Free Trial

ANI Pharmaceuticals Q2 2024 Earnings Report

ANI Pharmaceuticals logo
$58.64 -0.92 (-1.54%)
As of 01/31/2025 04:00 PM Eastern

ANI Pharmaceuticals EPS Results

Actual EPS
$1.02
Consensus EPS
$0.95
Beat/Miss
Beat by +$0.07
One Year Ago EPS
$1.06

ANI Pharmaceuticals Revenue Results

Actual Revenue
$138.00 million
Expected Revenue
$129.09 million
Beat/Miss
Beat by +$8.91 million
YoY Revenue Growth
+18.50%

ANI Pharmaceuticals Announcement Details

Quarter
Q2 2024
Time
Before Market Opens

Conference Call Resources

Conference Call Audio

ANI Pharmaceuticals Earnings Headlines

ANI Pharmaceuticals (NASDAQ:ANIP) Cut to Sell at StockNews.com
Elon’s #1 AI Stock” SET TO SOAR
Forget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.
ANI Pharmaceuticals (ANIP) Receives a Buy from Raymond James
See More ANI Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like ANI Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ANI Pharmaceuticals and other key companies, straight to your email.

About ANI Pharmaceuticals

ANI Pharmaceuticals (NASDAQ:ANIP), a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

View ANI Pharmaceuticals Profile

More Earnings Resources from MarketBeat